A Brazilian court has stripped the patent protection of a company selling hepatitis C treatment in the country. A presidential candidate pushed for the move against Gilead Sciences Inc to pave the way for cheaper generics.
The ruling invalidates the exclusivity patent for the drug sofosbuvir – sold as Sovaldi. The request was filed early September by presidential candidate Marina Silva and her running mate, with them stating such a move would significantly reduce costs for patients.
Gilead came under criticism for prices of $1,000 a pill in the US. India, along with other nations and consumer groups have also challenged patents on the drug.